BeOne Medicines (BEIGF) Net Margin (2015 - 2026)

BeOne Medicines (BEIGF) has 12 years of Net Margin data on file, last reported at 15.02% in Q1 2026.

• Net Margin for Q1 2026 came in at 15.02%, up 1491.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 8.94% (up 1833.0% YoY), and the FY2025 annual result was 5.37%, up 2229.0% from the prior year.
• Net Margin improved to 15.02% in Q1 2026 per BEIGF's latest filing, from 4.44% in the prior quarter.
• Over five years, Net Margin peaked at 27.57% in Q3 2023 and troughed at 165.62% in Q2 2022.
• A 5-year average of 45.71% and a median of 13.47% in 2024 frame the typical range for Net Margin.
• The sharpest annual moves came in 2022 and 2023: Net Margin tumbled 15291 bps in 2022, then soared 17141 bps in 2023.
• A 5-year view of Net Margin shows it stood at 117.16% in 2022, then jumped by 51 bps to 57.94% in 2023, then soared by 77 bps to 13.47% in 2024, then surged by 133 bps to 4.44% in 2025, then soared by 238 bps to 15.02% in 2026.
• Business Quant data shows BEIGF's Net Margin at 15.02% in Q1 2026, 4.44% in Q4 2025, and 8.84% in Q3 2025.